Showing 4511-4520 of 5771 results for "".
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- Pooled Analysis of Data from Two Phase 3 Clinical Trials of Upneeq for Acquired Ptosis Publishedhttps://modernod.com/news/pooled-analysis-of-data-from-two-phase-3-clinical-trials-of-upneeq-for-acquired-ptosis-published/2478357/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that JAMA Ophthalmology has published pooled analysis of data from two phase 3 clinical trials of Upneeq (oxymetazoline hydrochloride ophthalmic solution) 0.1% for treatment of acquired blepharoptosis (
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- iSTAR Medical Reports Positive 6-Month Data for MINIject Devicehttps://modernod.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/iSTAR Medical announced that its microinvasive glaucoma surgery (MIGS) device MINIject showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supracilia
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Biotech Healthcare Launches Optiflex TRIO Trifocal IOL in Europehttps://modernod.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/Switzerland-based Biotech Healthcare has announced the European launch of the Optiflex Trio, a diffractive-refractive trifocal toric IOL designed to treat presbyopia and with astigmatism. Its unique diffraction pattern gives a balanced light distribution at all three distances: near, intermediate
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- Oxurion to Present New Preclinical Data on THR-687 at EURETINA 2020 Virtual Meetinghttps://modernod.com/news/oxurion-to-present-new-preclinical-data-on-thr-687-at-euretina-2020-virtual-meeting/2478342/Oxurion NV announced that it will present new preclinical data on THR-687 at the European Society of Retina Specialists (EURETINA) 2020 Virtual Meeting taking place October 2-4. The company will make two presentations on preclinical data at the meeting as follows (sessions are virtual so h
- Alcon Focuses on Presbyopia-Correcting IOL Innovation and the New Normal at the Virtual ESCRS 2020https://modernod.com/news/alcon-focuses-on-presbyopia-correcting-iol-innovation-and-the-new-normal-at-the-virtual-escrs-2020/2478344/Alcon will host several events and present new technologies in cataract surgery during the virtual European Society of Cataract and Refractive Surgery (ESCRS) 2020 annual meeting, taking place October 2-4. “As
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c